In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Novo Nordisk

Status: Completed

Conditions: Overweight; Obesity

Treatments: Drug: Liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT03479762

EUPAS23369 (Registry Identifier)

U1111-1185-3276 (Other Identifier)

NN8022-4246

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.

Enrollment: 105 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date (time of first prescription). Patients must be research standard (registered as "acceptable" in the database) with at least one year of up-to-standard registration prior to their index date

Exclusion criteria

-Not applicable

Trial design

105 participants in 1 patient group

Liraglutide

Description:

Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)

Treatment:

Drug: Liraglutide